Gottfried Von Keudell, Md Phd

This phase 2 study is testing whether combining rituximab (an antibody) with venetoclax (a targeted pill) can improve outcomes for people with untreated marginal zone lymphoma. About 33 participants will receive the combination, and researchers will measure how many achieve a com…

This phase 2 trial is testing whether epcoritamab, a type of antibody, can help people with Waldenstrom Macroglobulinemia (a rare blood cancer) who have already received treatment. The study will enroll 20 participants and measure how many respond to the drug. Epcoritamab is give…

This study tests a drug called odronextamab in people with a slow-growing blood cancer (follicular lymphoma) who have not had treatment before and have low tumor burden. The goal is to see if the drug can shrink or eliminate the cancer. About 35 adults will receive the drug, and …